{"organizations": [], "uuid": "526a1b401408e15d5f8f52ca453dd330b3a8305e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/merck-co-study/mercks-keytruda-succeeds-late-stage-lung-cancer-study-idUSL3N1SU480", "country": "US", "domain_rank": 408, "title": "Merck's Keytruda succeeds late-stage lung cancer study", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-23T14:00:00.000+03:00", "replies_count": 0, "uuid": "526a1b401408e15d5f8f52ca453dd330b3a8305e"}, "author": "", "url": "https://www.reuters.com/article/merck-co-study/mercks-keytruda-succeeds-late-stage-lung-cancer-study-idUSL3N1SU480", "ord_in_thread": 0, "title": "Merck's Keytruda succeeds late-stage lung cancer study", "locations": [], "entities": {"persons": [{"name": "keytruda", "sentiment": "negative"}, {"name": "manas mishra", "sentiment": "none"}, {"name": "shailesh kuber", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}], "organizations": [{"name": "merck", "sentiment": "negative"}, {"name": "merck & co", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 23, 2018 / 11:01 AM / in 10 minutes Merck's Keytruda succeeds late-stage lung cancer study Reuters Staff 1 Min Read\nMay 23 (Reuters) - Merck & Co on Wednesday said its cancer drug Keytruda had met the main goals of a late-stage study testing it in combination with chemotherapy for a type of lung cancer.\nKeytruda, which is already approved, is the only immunotherapy approved in the United States to treat lung cancer patients who have not received prior treatment.\nKeytruda helped extend survival and prevented the disease from progressing as a first-line treatment for metastatic squamous non-small cell lung cancer patients. (Reporting by Manas Mishra in Bengaluru; Editing by Shailesh Kuber)", "external_links": [], "published": "2018-05-23T14:00:00.000+03:00", "crawled": "2018-05-23T14:17:50.011+03:00", "highlightTitle": ""}